Balyasny Asset Management
CTXR icon

Balyasny Asset Management’s Citius Pharmaceuticals CTXR Stock Holding History

Balyasny Asset Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,082
Closed -$15.8K – 2806
2024
Q2 		$15.8K Buy
+1,082
New +$19.4K ﹤0.01% 2479

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCC
Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

Balyasny Asset Management's CTXR Position: Q3 2024 in Review

Balyasny Asset Management sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 1,082 shares — an estimated $15.8K sold.

Balyasny Asset Management first reported a position in CTXR in Q2 2024 and held it in 1 quarter. The position peaked at $15.8K in Q2 2024. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

  • Balyasny Asset Management reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 1,082 Citius Pharmaceuticals shares in Q3 2024, an estimated $15.8K.
  • Balyasny Asset Management first reported a position in Citius Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Balyasny Asset Management's Citius Pharmaceuticals position peaked at $15.8K in Q2 2024.
  • 57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.